Chemoimmunotherapy with or without radiation before surgery for advanced mouth cancer
Part of Cancer clinical trials.
This trial tests whether adding targeted radiation (SBRT) to a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with advanced mouth or throat cancer. It aims to shrink the tumor more effectively before removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell carcinoma of the mouth or throat that can be surgically removed and is stage III or IVa.
- You are between 18 and 65 years old.
- You are in good overall health (able to care for yourself and be up and about more than half of your waking hours).
- Your blood counts, liver, kidney, and clotting function are within acceptable ranges (your doctor will check).
- You have not had previous treatment with certain immune therapy drugs (like anti-PD-1 or anti-CTLA-4).
- You do not have active autoimmune disease, other cancers, serious heart/lung problems, or active infections like HIV or hepatitis B/C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced oral squamous cell carcinoma. The treatment is given first to shrink the tumor, then again after surgery to help prevent recurrence.
This trial tests a combination of three drugs (adebrelimab, carboplatin, and albumin-bound paclitaxel) before surgery for people with advanced mouth cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes.
This trial tests a combination of low-dose radiation, immunotherapy, and chemotherapy for people with advanced oral squamous cell carcinoma (a type of mouth cancer) who have not had any prior cancer treatment. The goal is to see if this approach can shrink tumors safely.
This trial tests whether adding two immunotherapy drugs (sintilimab and cetuximab) before and after surgery can improve outcomes for people with advanced mouth or throat cancer. It is for those who have not yet had treatment and whose tumors have a certain protein level (PD-L1 CPS >1).
This trial tests a new combination of two drugs (sacituzumab govitecan and toripalimab) given before surgery to shrink advanced oral cavity tumors. The goal is to see if this approach helps make surgery more effective and improves outcomes.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) given before surgery to treat mouth or throat cancer that has come back. The goal is to shrink the tumor and improve surgery outcomes.
Hear when a new Oropharyngeal Squamous Cell Carcinoma (SCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.